Gavin Guo

Mr. Guo has provided legal services such as transaction structure design, due diligence, drafting, review, and negotiation of transaction documents for hundreds of investment, financing, and M&A deals. Mr. Guo’s experience covers various industry sectors including healthcare, semiconductors, consumer goods, TMT and education.
Especially in the healthcare sector, Mr. Guo can provide clients with a full range of legal services, including company structure establishment, private equity financing, mergers and acquisitions, license-in/out transactions, and equity incentives.
In addition, Mr. Guo also provides legal services with respect to the establishment of private equity funds, and the Initial public offering. He has accompanied the growth of many well-known enterprises and provided full-cycle legal services to clients.

REPRESENTATIVE MATTERS AND CASES

• Representing China Resources Pharmaceutical (03320.HK), China Resources Zizhu, China Resources Sanjiu (000999.SZ), and China Resources Double Crane (600062.SH) in multiple asset transactions and product cooperation projects.
• Providing legal services for a series of technology transactions for XtalPi Technology (02228.HK).
• Advising GenFleet Pharmaceutical on a license-out transaction for its KRAS G12C Inhibitor (GFH925)  with Innovent Biologics, a license-out transaction for a CDK9 small molecule inhibitor with SELLAS Life Sciences Group (NDAQ: SLS), and a collaboration transaction regarding a CXCR4 inhibitor with BioLineRx (NDAQ: BLRX).
• Representing Yiming Kangda in its license-out transactions with Chia Tai Tianqing and Hualan Bio (002007.SZ).
• Advising Sinotau Pharmaceutical on multiple international and domestic pipeline cooperation transactions, including projects involving ADCs and radionuclide drugs.
• Assisting Escugen Bio in securing a license-out agreement for an ADC drug with an overseas partner.
• Representing CoJourney Bio in executing a technology collaboration transaction.
• Facilitating financing transactions for companies such as Sironax, Huahui Anjian, GenFleet Pharmaceutical, Nanos Medical, MAB WORKS, and Yiming Kangda.
• Representing Sequoia China in investments across projects including Gempharmatech, AccuMedical, Shukun Technology, Infervision Technology, and Xihu Bio.
• Advising IDG Capital on its investments in Caike Bio and Gensciences.
• Assisting River Head Capital in its investment in Chaoju Eye Care.
• Representing WuXi AppTec in its acquisition of pharmaceutical manufacturing facilities

Honors and Awards

• 2024-2025 Recognized in Chambers Greater China Region for Private Equity
• 2022-2025 Recognized in The Legal 500 for Private Equity
• 2024 Recognized in LEGALBAND for Life Sciences
• 2024 Named to China Business Law Journal (CBLJ) The A-List: Rising Stars
• 2023 Named a LEGALBAND Top 20 Lawyer in New Economy

Work Language

• English
• Mandarin